Principal Investigator
Noa Holtzman
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20241257
Clinical Trial Summary
A Phase II Randomized Study of Ruxolitinib vs Prednisone as First-Line Therapy for Chronic Graft vs Host Disease (cGVHD) Needing Systemic Therapy
Phase
Phase II
Funding Agency/Sponsor
Institutional
Disease
Transplant/cellular therapy
Contact Information
Phone Number
305-243-2647